Tumor Organoids as a Pre-clinical Cancer Model for Drug Discovery

Cell Chemical Biology

Volumn 24, Issue 9, 2017, Pages 1092-1100

  Weeber, Fleur ^a   Ooft, Salo N ^a   Dijkstra, Krijn K ^a   Voest, Emile E ^a,b,c  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b Foundation Hubrecht Organoid Technology   (Netherlands)

^c Cancer GenomiCsnl   (Netherlands)

Author keywords

biobank; cell line; drug development; drug screen; patient derived tumor organoids; patient derived xenograft; PDX; three dimensional culture; tumor organoids

Indexed keywords

BIOBANK; BREAST TUMOR; CANCER CELL; CANCER CELL CULTURE; CANCER MODEL; CELL HETEROGENEITY; COLORECTAL TUMOR; CYSTIC FIBROSIS; CYTOPLASM; DRUG DESIGN; DRUG RESPONSE; DRUG SCREENING; EPITHELIUM CELL; EX VIVO STUDY; EXPERIMENTAL NEOPLASM; GENETICS; HUMAN; HUMAN CELL; IMMUNE SYSTEM; IN VITRO STUDY; PANCREAS TUMOR; PHENOTYPE; PRECLINICAL STUDY; PRIORITY JOURNAL; PROSTATE TUMOR; REVIEW; STROMAL CELL LINE; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR ORGANOIDS; VALIDATION STUDY; ANIMAL; BIOLOGICAL MODEL; CELL CULTURE TECHNIQUE; CRISPR CAS SYSTEM; DRUG DEVELOPMENT; METABOLISM; NEOPLASM; PATHOLOGY;

ANTINEOPLASTIC AGENT; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CULTURE TECHNIQUES; CRISPR-CAS SYSTEMS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DRUG DISCOVERY; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85026212686     PISSN: 24519456     EISSN: 24519448     Source Type: Journal    
DOI: 10.1016/j.chembiol.2017.06.012     Document Type: Review

References (64)

1. Bartfeld, S., Clevers, H., Organoids as model for infectious diseases: culture of human and murine stomach organoids and microinjection of Helicobacter pylori. J. Vis. Exp., 105, 2015, 10.3791/53359.
2. Bartfeld, S., Bayram, T., van de Wetering, M., Huch, M., Begthel, H., Kujala, P., Vries, R., Peters, P.J., Clevers, H., In vitro expansion of human gastric epithelial stem cells and their responses to bacterial infection. Gastroenterology 148 (2015), 126–136.e6.
3. Begley, C.G., Ellis, L.M., Drug development: raise standards for preclinical cancer research. Nature 483 (2012), 531–533.
4. Behjati, S., Huch, M., van Boxtel, R., Karthaus, W., Wedge, D.C., Tamuri, A.U., Martincorena, I., Petljak, M., Alexandrov, L.B., Gundem, G., et al. Genome sequencing of normal cells reveals developmental lineages and mutational processes. Nature 513 (2014), 422–425.
5. Bertotti, A., Migliardi, G., Galimi, F., Sassi, F., Torti, D., Isella, C., Cora, D., Di, N.F., Buscarino, M., Petti, C., et al. A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 1 (2011), 508–523.
6. Boj, S.F., Hwang, C.I., Baker, L.A., Chio, I.I., Engle, D.D., Corbo, V., Jager, M., Ponz-Sarvise, M., Tiriac, H., Spector, M.S., et al. Organoid models of human and mouse ductal pancreatic cancer. Cell 160 (2015), 324–338.
7. Borst, P., Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what?. Open Biol., 2, 2012, 120066.
8. Bruna, A., Rueda, O.M., Greenwood, W., Batra, A.S., Callari, M., Batra, R.N., Pogrebniak, K., Sandoval, J., Cassidy, J.W., Tufegdzic-Vidakovic, A., et al. A biobank of breast cancer explants with preserved intra-tumor heterogeneity to screen anticancer compounds. Cell 167 (2016), 260–274.e22.
9. Byrne, A.T., Alférez, D.G., Amant, F., Annibali, D., Arribas, J., Biankin, A.V., Bruna, A., Budinská, E., Caldas, C., Chang, D.K., et al. Interrogating open issues in cancer precision medicine with patient-derived xenografts. Nat. Rev. Cancer 17 (2017), 254–268.
10. Clevers, H., Modeling development and disease with organoids. Cell 165 (2016), 1586–1597.
11. Dangles-Marie, V., Pocard, M., Richon, S., Weiswald, L.B., Assayag, F., Saulnier, P., Judde, J.G., Janneau, J.L., Auger, N., Validire, P., et al. Establishment of human colon cancer cell lines from fresh tumors versus xenografts: comparison of success rate and cell line features. Cancer Res. 67 (2007), 398–407.
12. Dekkers, J.F., van der Ent, C.K., Beekman, J.M., Novel opportunities for CFTR-targeting drug development using organoids. Rare Dis., 1, 2013, e27112.
13. Dekkers, J.F., Wiegerinck, C.L., de Jonge, H.R., Bronsveld, I., Janssens, H.M., de Winter-de Groot, K.M., Brandsma, A.M., de Jong, N.W., Bijvelds, M.J., Scholte, B.J., et al. A functional CFTR assay using primary cystic fibrosis intestinal organoids. Nat. Med. 19 (2013), 939–945.
14. Dekkers, J.F., Berkers, G., Kruisselbrink, E., Vonk, A., de Jonge, H.R., Janssens, H.M., Bronsveld, I., van de Graaf, E.A., Nieuwenhuis, E.E., Houwen, R.H., et al. Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis. Sci. Transl Med., 8, 2016, 344ra384.
15. Dekkers, J.F., Gogorza Gondra, R.A., Kruisselbrink, E., Vonk, A.M., Janssens, H.M., de Winter-de Groot, K.M., van der Ent, C.K., Beekman, J.M., Optimal correction of distinct CFTR folding mutants in rectal cystic fibrosis organoids. Eur. Respir. J. 48 (2016), 451–458.
16. Drost, J., van Jaarsveld, R.H., Ponsioen, B., Zimberlin, C., van Boxtel, R., Buijs, A., Sachs, N., Overmeer, R.M., Offerhaus, G.J., Begthel, H., et al. Sequential cancer mutations in cultured human intestinal stem cells. Nature 521 (2015), 43–47.
17. Fischel, J.L., Etienne, M.C., Formento, P., Milano, G., Search for the optimal schedule for the oxaliplatin/5-fluorouracil association modulated or not by folinic acid: preclinical data. Clin. Cancer Res. 4 (1998), 2529–2535.
18. Fujii, M., Shimokawa, M., Date, S., Takano, A., Matano, M., Nanki, K., Ohta, Y., Toshimitsu, K., Nakazato, Y., Kawasaki, K., et al. A colorectal tumor organoid library demonstrates progressive loss of niche factor requirements during tumorigenesis. Cell Stem Cell 18 (2016), 827–838.
19. Gao, D., Vela, I., Sboner, A., Iaquinta, P.J., Karthaus, W.R., Gopalan, A., Dowling, C., Wanjala, J.N., Undvall, E.A., Arora, V.K., et al. Organoid cultures derived from patients with advanced prostate cancer. Cell 159 (2014), 176–187.
20. Gao, H., Korn, J.M., Ferretti, S., Monahan, J.E., Wang, Y., Singh, M., Zhang, C., Schnell, C., Yang, G., Zhang, Y., et al. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. Nat. Med. 21 (2015), 1318–1325.
21. Gjorevski, N., Sachs, N., Manfrin, A., Giger, S., Bragina, M.E., Ordonez-Moran, P., Clevers, H., Lutolf, M.P., Designer matrices for intestinal stem cell and organoid culture. Nature 539 (2016), 560–564.
22. Hafner, M., Niepel, M., Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs. Nat. Methods 13 (2016), 521–527.
23. Harris, L.A., Frick, P.L., Garbett, S.P., Hardeman, K.N., Paudel, B.B., Lopez, C.F., Quaranta, V., Tyson, D.R., An unbiased metric of antiproliferative drug effect in vitro. Nat. Methods 13 (2016), 497–500.
24. Hay, M., Thomas, D.W., Craighead, J.L., Economides, C., Rosenthal, J., Clinical development success rates for investigational drugs. Nat. Biotechnol. 32 (2014), 40–51.
25. Hidalgo, M., Bruckheimer, E., Rajeshkumar, N.V., Garrido-Laguna, I., De, O.E., Rubio-Viqueira, B., Strawn, S., Wick, M.J., Martell, J., Sidransky, D., A pilot clinical study of treatment guided by personalized tumor grafts in patients with advanced cancer. Mol. Cancer Ther. 10 (2011), 1311–1316.
26. Hidalgo, M., Amant, F., Biankin, A.V., Budinska, E., Byrne, A.T., Caldas, C., Clarke, R.B., de Jong, S., Jonkers, J., Maelandsmo, G.M., et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 4 (2014), 998–1013.
27. Huang, L., Holtzinger, A., Jagan, I., BeGora, M., Lohse, I., Ngai, N., Nostro, C., Wang, R., Muthuswamy, L.B., Crawford, H.C., et al. Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids. Nat. Med. 21 (2015), 1364–1371.
28. Huch, M., Boj, S.F., Clevers, H., Lgr5(+) liver stem cells, hepatic organoids and regenerative medicine. Regen. Med. 8 (2013), 385–387.
29. Huch, M., Gehart, H., van Boxtel, R., Hamer, K., Blokzijl, F., Verstegen, M.M., Ellis, E., van Wenum, M., Fuchs, S.A., de Ligt, J., et al. Long-term culture of genome-stable bipotent stem cells from adult human liver. Cell 160 (2015), 299–312.
30. Iorio, F., Knijnenburg, T.A., Vis, D.J., Bignell, G.R., Menden, M.P., Schubert, M., Aben, N., Goncalves, E., Barthorpe, S., Lightfoot, H., et al. A landscape of pharmacogenomic interactions in cancer. Cell 166 (2016), 740–754.
31. Junttila, M.R., de Sauvage, F.J., Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 501 (2013), 346–354.
32. Karthaus, W.R., Iaquinta, P.J., Drost, J., Gracanin, A., van Boxtel, R., Wongvipat, J., Dowling, C.M., Gao, D., Begthel, H., Sachs, N., et al. Identification of multipotent luminal progenitor cells in human prostate organoid cultures. Cell 159 (2014), 163–175.
33. Leto, S.M., Sassi, F., Catalano, I., Torri, V., Migliardi, G., Zanella, E.R., Throsby, M., Bertotti, A., Trusolino, L., Sustained inhibition of HER3 and EGFR is necessary to induce regression of HER2-amplified gastrointestinal carcinomas. Clin. Cancer Res. 21 (2015), 5519–5531.
34. Li, X., Nadauld, L., Ootani, A., Corney, D.C., Pai, R.K., Gevaert, O., Cantrell, M.A., Rack, P.G., Neal, J.T., Chan, C.W., et al. Oncogenic transformation of diverse gastrointestinal tissues in primary organoid culture. Nat. Med. 20 (2014), 769–777.
35. Lin, D., Wyatt, W., Xue, H., Wang, Y., Dong, X., Haegert, A., Wu, R., Brahmbhatt, S., Mo, F., Jong, L., et al. High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. Cancer Res. 74 (2014), 1272–1283.
36. Liu, X., Ory, V., Chapman, S., Yuan, H., Albanese, C., Kallakury, B., Timofeeva, O.A., Nealon, C., Dakic, A., Simic, V., et al. ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells. Am. J. Pathol. 180 (2012), 599–607.
37. Liu, C., Liu, Y., Xie, H.G., Zhao, S., Xu, X.X., Fan, L.X., Guo, X., Lu, T., Sun, G.W., Ma, X.J., Role of three-dimensional matrix stiffness in regulating the chemoresistance of hepatocellular carcinoma cells. Biotechnol. Appl. Biochem. 62 (2015), 556–562.
38. Matano, M., Date, S., Shimokawa, M., Takano, A., Fujii, M., Ohta, Y., Watanabe, T., Kanai, T., Sato, T., Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids. Nat. Med. 21 (2015), 256–262.
39. Nadauld, L.D., Garcia, S., Natsoulis, G., Bell, J.M., Miotke, L., Hopmans, E.S., Xu, H., Pai, R.K., Palm, C., Regan, J.F., et al. Metastatic tumor evolution and organoid modeling implicate TGFBR2 as a cancer driver in diffuse gastric cancer. Genome Biol., 15, 2014, 428.
40. Noordhoek, J., Gulmans, V., van der Ent, K., Beekman, J.M., Intestinal organoids and personalized medicine in cystic fibrosis: a successful patient-oriented research collaboration. Curr. Opin. Pulm. Med. 22 (2016), 610–616.
41. Nozaki, K., Mochizuki, W., Matsumoto, Y., Matsumoto, T., Fukuda, M., Mizutani, T., Watanabe, M., Nakamura, T., Co-culture with intestinal epithelial organoids allows efficient expansion and motility analysis of intraepithelial lymphocytes. J. Gastroenterol. 51 (2016), 206–213.
42. Ootani, A., Li, X., Sangiorgi, E., Ho, Q.T., Ueno, H., Toda, S., Sugihara, H., Fujimoto, K., Weissman, I.L., Capecchi, M.R., et al. Sustained in vitro intestinal epithelial culture within a Wnt-dependent stem cell niche. Nat. Med. 15 (2009), 701–706.
43. Pauli, C., Hopkins, B.D., Prandi, D., Shaw, R., Fedrizzi, T., Sboner, A., Sailer, V., Augello, M., Puca, L., Rosati, R., et al. Personalized in vitro and in vivo cancer models to guide precision medicine. Cancer Discov. 7 (2017), 462–477.
44. Porter, S.N., Baker, L.C., Mittelman, D., Porteus, M.H., Lentiviral and targeted cellular barcoding reveals ongoing clonal dynamics of cell lines in vitro and in vivo. Genome Biol., 15, 2014, R75.
45. Rubin, E.H., Gilliland, D.G., Drug development and clinical trials–the path to an approved cancer drug. Nat. Rev. Clin. Oncol. 9 (2012), 215–222.
46. Rückert, F., Aust, D., Böhme, I., Werner, K., Brandt, A., Diamandis, E.P., Krautz, C., Hering, S., Saeger, H.D., Grützmann, R., et al. Five primary human pancreatic adenocarcinoma cell lines established by the outgrowth method. J. Surg. Res. 172 (2012), 29–39.
47. Russo, M., Siravegna, G., Blaszkowsky, L.S., Corti, G., Crisafulli, G., Ahronian, L.G., Mussolin, B., Kwak, E.L., Buscarino, M., Lazzari, L., et al. Tumor heterogeneity and lesion-specific response to targeted therapy in colorectal cancer. Cancer Discov. 6 (2016), 147–153.
48. Sato, T., Vries, R.G., Snippert, H.J., van de Wetering, M., Barker, N., Stange, D.E., van Es, J.H., Abo, A., Kujala, P., Peters, P.J., et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 459 (2009), 262–265.
49. Sato, T., Stange, D.E., Ferrante, M., Vries, R.G., Van Es, J.H., Van den Brink, S., Van Houdt, W.J., Pronk, A., Van Gorp, J., Siersema, P.D., et al. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. Gastroenterology 141 (2011), 1762–1772.
50. Schutte, M., Risch, T., Abdavi-Azar, N., Boehnke, K., Schumacher, D., Keil, M., Yildiriman, R., Jandrasits, C., Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors. Nat. Commun., 8, 2017, 14262.
51. Schwank, G., Koo, B.K., Sasselli, V., Dekkers, J.F., Heo, I., Demircan, T., Sasaki, N., Boymans, S., Cuppen, E., van der Ent, C.K., et al. Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. Cell Stem Cell 13 (2013), 653–658.
52. Snippert, H.J., Schepers, A.G., van Es, J.H., Simons, B.D., Clevers, H., Biased competition between Lgr5 intestinal stem cells driven by oncogenic mutation induces clonal expansion. EMBO Rep. 15 (2014), 62–69.
53. Stein, W.D., Litman, T., Fojo, T., Bates, S.E., A Serial Analysis of Gene Expression (SAGE) database analysis of chemosensitivity: comparing solid tumors with cell lines and comparing solid tumors from different tissue origins. Cancer Res. 64 (2004), 2805–2816.
54. Sun, C., Hobor, S., Bertotti, A., Zecchin, D., Huang, S., Galimi, F., Cottino, F., Prahallad, A., Grernrum, W., Tzani, A., et al. Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3. Cell Rep. 7 (2014), 86–93.
55. Szakacs, G., Gottesman, M.M., Comparing solid tumors with cell lines: implications for identifying drug resistance genes in cancer. Mol. Interv. 4 (2004), 323–325.
56. Turner, N.C., Reis-Filho, J.S., Genetic heterogeneity and cancer drug resistance. Lancet Oncol. 13 (2012), e178–185.
57. van de Wetering, M., Francies, H.E., Francis, J.M., Bounova, G., Iorio, F., Pronk, A., van Houdt, W., van Gorp, J., Clevers, H., Prospective derivation of a ‘Living Organoid Biobank’ of colorectal cancer patients. Cell 161 (2015), 933–945.
58. Verissimo, C.S., Overmeer, R.M., Ponsioen, B., Drost, J., Mertens, S., Verlaan-Klink, I., Gerwen, B.V., van der Ven, M., Wetering, M.V., Egan, D.A., et al. Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening. eLife, 5, 2016, 10.7554/eLife.18489.
59. Vermeulen, L., Morrissey, E., van der Heijden, M., Nicholson, A.M., Sottoriva, A., Buczacki, S., Kemp, R., Tavare, S., Winton, D.J., Defining stem cell dynamics in models of intestinal tumor initiation. Science 342 (2013), 995–998.
60. Vidovic, D., Carlon, M.S., da Cunha, M.F., Dekkers, J.F., Hollenhorst, M.I., Bijvelds, M.J., Ramalho, A.S., Van den Haute, C., Ferrante, M., Baekelandt, V., et al. rAAV-CFTRDeltaR rescues the cystic fibrosis phenotype in human intestinal organoids and cystic fibrosis mice. Am. J. Respir. Crit. Care Med. 193 (2016), 288–298.
61. Voest, E.E., Bernards, R., DNA-Guided precision medicine for cancer: a case of irrational exuberance?. Cancer Discov. 6 (2016), 130–132.
62. Weeber, F., Van de Wetering, M., Hoogstraat, M., Dijkstra, K.K., Krijgsman, O., Kuilman, T., Gadellaa-van Hooijdonk, C.G., Van der Velden, D.V., Cuppen, E., Vries, R.G., et al. Preserved genomic diversity in organoids cultured from biopsies of colorectal cancer metastases. Proc. Natl. Acad. Sci. USA 112 (2015), 13308–13311.
63. Wilding, J.L., Bodmer, W.F., Cancer cell lines for drug discovery and development. Cancer Res. 74 (2014), 2377–2384.
64. Zhang, X., Claerhout, S., Prat, A., Dobrolecki, L.E., Petrovic, I., Lai, Q., Landis, M.D., Wiechmann, L., Schiff, R., Giuliano, M., et al. A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res. 73 (2013), 4885–4897.